- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
- News News
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit
- Join Join
Washington, DC -- In light of the emergence of Vaping-Associated Pulmonary Illness (VAPI), which has sickened at least 805 people and killed 12, Americans for Safe Access (ASA) strongly recommends that patients and consumers stop using cannabis-containing cartridges entirely (or at least to the extent possible) until there is clarity as to what is causing these illnesses and deaths. Patients and consumers are encouraged to use other legal delivery mechanisms that may be available to them in their state, such as dry herb (flower) vaporizers, tinctures, edibles, or topicals.
ASA does not support outright bans on cannabis-containing cartridges or devices intended for the consumption of cannabis concentrates, which could cause more people to the unregulated market and exacerbate the spread of VAPI. Rather, we recommend bans on the inclusion of any additives (e.g., diluents, thickeners, flavoring agents) not derived from cannabis. Additionally, we urge that patients and consumers only purchase cannabis products that have undergone testing at an independent, third-party laboratory that has verified composition and potency and screened for adulterants, contaminants, heavy metals, residual solvents, chemical residues, and other health concerns, such as mold and dangerous bacteria.
The current health crisis highlights the importance of legalization, regulation, laboratory testing of all cannabis and cannabis-derived products (most critically when they are in their final form), and third-party certification, such as that offered through ASA's Patient Focused Certification (PFC) program. Since 2014, ASA has urged the industry to adopt third-party certification for all cannabis businesses. Through the PFC program, companies are required to adhere to safety, quality, manufacturing, testing, packaging, and labeling standards beyond those set by most jurisdictions where the medical and/or adult use of cannabis has been legalized. PFC companies are subject to both routine and unannounced inspections by independent auditors, which is especially important in light of the fact that jurisdictions may not have enough inspectors to ensure that all licensed operators are complying with all regulations. To ensure consumer safety and product quality, ASA recommends that patients and consumers ask about third-party certification at their local dispensaries.
“Americans for Safe Access started out in 2002 with the mission to not just ensure access to medical cannabis to patients across the county, but to ensure safe access,” said Americans for Safe Access Interim Director Debbie Churgai. “As a patient-focused organization, we take the safety of patients very seriously, and the emergence of VAPI has caused us great concern. We will continue to do our part for patients, who are and always will be our highest priority, by keeping up the pressure on industry to adopt regulations that promote patient and consumer safety and by persisting in our advocacy for safe access to medical cannabis for patients everywhere,” she said.
Recommendations can be found here: https://www.safeaccessnow.org/patient_focused_recommendations_regarding_the_vaping_crisis